Capecitabine maintenance therapy after first-line chemotherapy in patients with metastatic colorectal cancer

Chinese Journal of Cancer Research

Volumn 22, Issue 3, 2010, Pages 181-185

  Li, Yan ^a,b   Li, Jing ^a,b   Lu, Ming ^a,b   Wang, Xi Cheng ^a,b   Shen, Lin ^a,b  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Capecitabine; Metastatic colorectal cancer

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAND FOOT SYNDROME; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; REPEATED DRUG DOSE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77956834902     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.1007/s11670-010-0181-x     Document Type: Article

References (25)

1. A. Grothey D. Sargent R.M. Goldberg, et al. 2004 Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment[J] J Clin Oncol 22 1209 1214 1:CAS:528:DC%2BD2cXpsVGktLo%3D 10.1200/JCO.2004.11.037 15051767
2. C. Tournigand T. André E. Achille, et al. 2004 FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study[J] J Clin Oncol 22 229 237 1:CAS:528:DC%2BD2cXpsVKit7w%3D 10.1200/JCO.2004.05.113 14657227
3. A. Grothey D. Sargent 2005 Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line[J] J Clin Oncol 23 9441 9442 10.1200/JCO.2005.04.4792 16361649
4. C. Tournigand A. Cervantes A. Figer, et al. 2006 OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study[J] J Clin Oncol 24 394 400 1:CAS:528:DC%2BD28XhsFSku7w%3D 10.1200/JCO.2005.03.0106 16421419
5. B. Chibaudel F. Maindrault-Goebel G. Lledo, et al. 2009 Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study[J] J Clin Oncol 27 5727 5733 1:CAS:528:DC%2BC3cXhtVWisbo%3D 10.1200/JCO.2009.23.4344 19786657
6. P. Tyagi A. Grothey 2006 Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial[J] Clin Colorectal Cancer 6 261 264 1:CAS:528: DC%2BD2sXhsVSmtrw%3D 10.3816/CCC.2006.n.044 17241510
7. A. Carrato J. Gallego-Plazas C. Guillén-Ponce 2008 Capecitabine plus oxaliplatin for the treatment of colorectal cancer [J] Expert Rev Anticancer Ther 8 161 174 1:CAS:528:DC%2BD1cXitlOgsbk%3D 10.1586/14737140.8.2. 161 18279056
8. L.B. Saltz J.Y. Douillard N. Pirotta, et al. 2001 Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard[J] Oncologist 6 81 91 1:CAS:528:DC%2BD3MXhtlKjtrw%3D 10.1634/theoncologist.6-1-81 11161231
9. M.L. Rothenberg A.M. Oza R.H. Bigelow, et al. 2003 Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial[J] J Clin Oncol 21 2059 2069 1:CAS:528:DC%2BD2cXpsVGqtL4%3D 10.1200/JCO.2003.11.126 12775730
10. A. Grothey R.M. Goldberg 2004 A review of oxaliplatin and its clinical use in colorectal cancer [J] Expert Opin Pharmacother 5 2159 2170 1:CAS:528:DC%2BD2cXotVOntbY%3D 10.1517/14656566.5.10.2159 15461551
11. T.B. Gibson A. Grothey 2006 Do all patients with metastatic colorectal cancer need chemotherapy until disease progression?[J] Clin Colorectal Cancer 6 196 201 1:CAS:528:DC%2BD28XhtFKltr3E 10.3816/CCC.2006.n.035 17026788
12. R. Petrioli L. Paolelli S. Marsili, et al. 2006 FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer[J] Oncology 70 345 350 1:CAS:528:DC%2BD2sXisFWntw%3D%3D 10.1159/000098107 17179728
13. T. André C. Tournigand L. Mineur, et al. 2007 Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study[J] Ann Oncol 18 77 81 10.1093/annonc/mdl336 17030548
14. S.I. Jalal F.O. Ademuyiwa N.H. Hanna 2009 The role of maintenance chemotherapy in advanced nonsmall cell lung cancer[J] Curr Opin Oncol 21 110 115 1:CAS:528:DC%2BD1MXntFyltbY%3D 10.1097/CCO.0b013e328322cf49 19532011
15. S. Ramalingam C. Belani 2008 Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions[J] Oncologist 13 5 13 1:CAS:528:DC%2BD1cXivFGrt7o%3D 10.1634/theoncologist.13-S1-5 18263769
16. E. Van Cutsem C. Twelves J. Cassidy, et al. 2001 Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study[J] J Clin Oncol 19 4097 4106 11689577
17. R.G. Hahn C.G. Moertel A.J. Schutt, et al. 1975 A double-blind comparison of intensive course 5-fluorouracil by oral vs. intravenous route in the treatment of colorectal carcinoma[J] Cancer 35 1031 1035 1:STN:280: DyaE2M7htVGltA%3D%3D 10.1002/1097-0142(197504)35:4<1031::AID- CNCR2820350403>3.0.CO;2-N 1090358
18. T.S. Maughan R.D. James D.J. Kerr, et al. 2003 Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial[J] Lancet 361 457 464 1:CAS:528: DC%2BD3sXhtVahur8%3D 10.1016/S0140-6736(03)12461-0 12583944
19. L. Simkens J. Tol M. Koopman 2008 Current questions in the treatment of advanced colorectal cancer: the CAIRO studies of the Dutch Colorectal Cancer Group[J] Clin Colorectal Cancer 2 105 109 10.3816/CCC.2008.n.014
20. R.M. Goldberg M.L. Rothenberg E. Van Cutsem, et al. 2007 The continuum of care: a paradigm for the management of metastatic colorectal cancer [J] Oncologist 12 38 50 10.1634/theoncologist.12-1-38 17227899
21. A. Grothey M.P. Goetz 2004 Oxaliplatin plus oral fluoropyrimidines in colorectal cancer[J] Clin Colorectal Cancer 4 S37 S42 1:CAS:528: DC%2BD2cXls1Sjsr4%3D 10.3816/CCC.2004.s.006 15212704
22. R.M. Goldberg 2005 Advances in the treatment of metastatic colorectal cancer[J] Oncologist 10 40 48 1:CAS:528:DC%2BD28Xot1Gisg%3D%3D 10.1634/theoncologist.10-90003-40 16368870
23. M. Koopman N.F. Antonini J. Douma, et al. 2007 Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial[J] Lancet 370 135 142 1:CAS:528:DC%2BD2sXns12jtLo%3D 10.1016/S0140-6736(07)61086-1 17630036
24. Y.H. Li H.Y. Luo F.H. Wang, et al. 2010 Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer[J] J Cancer Res Clin Oncol 136 503 510 1:CAS:528:DC%2BC3cXit1Gls7Y%3D 10.1007/s00432-009-0682-5 19777259
25. M.T. Seymour T.S. Maughan J.A. Ledermann, et al. 2007 Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial Lancet 370 143 152 1:CAS:528:DC%2BD2sXns12jtLs%3D 10.1016/S0140-6736(07)61087-3 17630037